Pentavalent Meningococcal Vaccine Available for Order

Vaccines for Children (VFC) Provider:

On October 25, 2023, the Advisory Committee on Immunization Practices recommended that MenACWY-TT/MenB-FHbp may be administered to persons aged ≥10 years when both a quadrivalent meningococcal conjugate vaccine (MenACWY) and meningococcal B vaccine (MenB) are indicated at the same visit. These recommendations can be referenced here: Use of the Pfizer Pentavelent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices ― United States, 2023.

Meningococcal disease is a life-threatening invasive infection caused by Neisseria meningitidis. The pentavalent meningococcal vaccine (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer Inc.]) protects against five N. meningitidis serogroups A, B, C, W, and Y and is licensed for use among persons aged 10–25 years.

PenbrayaTM is the first pentavalent meningococcal vaccine approved for protection against serogroups A, B, C, W, and Y. Different MenB vaccines from different manufacturers are not interchangeable; therefore, when PenbrayaTM is administered, subsequent doses of single antigen MenB vaccine should be from the same manufacturer (Pfizer Inc.).

Availability through the Vaccines for Children (VFC) Program:

PenbrayaTM will be available for order through the ImpactSIIS Vaccine Ordering Management System (VOMS) beginning Wednesday, May 22, 2024.  Vaccine shipments will be facilitated by the federal vaccine distributor, McKesson, based on product availability.  PenbrayaTM ordered through the VFC Program is to be administered to appropriate individuals who meet the ACIP recommendation eligibility and VFC eligibility criteria.  

PenbrayaTM Product Information:

  • Product: Penbraya.
  • VOMS Order Set: VFC-Refrigerated.
  • Presentation: Single Dose Vials.
  • Minimum Order Quantity:  5 Doses.

Storage and Handling:

  • Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton.
  • The vial stopper and the tip cap and plunger of the prefilled syringe are not made with natural rubber latex.
  • The vaccine is supplied in a kit containing lyophilized MenACWY containing vial, a prefilled syringe containing the MenB component, and a vial adapter for access.
    • Needles are NOT supplied.
  • To prepare PenbrayaTM, reconstitute the lyophilized MenACWY component with the MenB component.
  • After reconstitution, administer PenbrayaTM immediately. A single dose is 0.5mL given intramuscularly.
  • Discard reconstituted vaccine if not used within four hours.

Planning Considerations: 

  • A VFC provider who serves patients who meet/may meet the vaccine recommendation criteria above will be able to order and administer PenbrayaTM to VFC-eligible patients.
  • PenbrayaTM can be ordered in increments of 5 doses.
  • VOMS is available for providers to place orders 24 hours a day, seven days a week. 
  • If a dose of PenbrayaTM is administered as the first dose of the MenB series, Pfizer’s Trumenba® vaccine MUST be used to complete the Men B series.

Please contact the Immunization Program if you have any questions.